Royal Bank of Canada
RY
Canadian Imperial Bank of Commerce
CM
The Toronto-Dominion Bank
TD
4
Bank of Nova Scotia
BNS
5
Bank of Montreal
BMO
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.